Journal of the Neurological Sciences
Volume 206, Issue 1 , Pages 49-57 , 15 January 2003

A synthetic heparin-mimicking polyanionic compound inhibits central nervous system inflammation

  • Michal Irony-Tur-Sinai

      Affiliations

    • Laboratory of Neuroimmunology, Department of Neurology, Hadassah University Hospital and Hebrew University Medical School, P.O. Box 12000, Jerusalem 91120, Israel
    • ,
  • Israel Vlodavsky

      Affiliations

    • Department of Oncology, Hadassah University Hospital and Hebrew University Medical School, Jerusalem 91120, Israel
    • ,
  • Shmuel A Ben-Sasson

      Affiliations

    • Department of Experimental Medicine and Cancer Research, Hadassah University Hospital and Hebrew University Medical School, Jerusalem 91120, Israel
    • ,
  • Florence Pinto

      Affiliations

    • Laboratory of Neuroimmunology, Department of Neurology, Hadassah University Hospital and Hebrew University Medical School, P.O. Box 12000, Jerusalem 91120, Israel
    • ,
  • Camille Sicsic

      Affiliations

    • Laboratory of Neuroimmunology, Department of Neurology, Hadassah University Hospital and Hebrew University Medical School, P.O. Box 12000, Jerusalem 91120, Israel
    • ,
  • Talma Brenner

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +972-2-6776957; fax: +972-2-6437782.
    • Laboratory of Neuroimmunology, Department of Neurology, Hadassah University Hospital and Hebrew University Medical School, P.O. Box 12000, Jerusalem 91120, Israel

Received 14 May 2002 ,Revised 14 August 2002 ,Accepted 15 August 2002.

References 

  1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992;10:153–187
  2. Steinman L. Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis. J. Exp. Med. 2001;194:F27–F30
  3. Hickey WF, Cohen JA, Burns JB. A quantitative immunohistochemical comparison of actively versus adoptively induced experimental allergic encephalomyelitis in the Lewis rat. Cell. Immunol. 1987;109:272–281
  4. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 2001;194:669–676
  5. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, et al.  Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 2001;166:7579–7587
  6. Cross AH, Trotter JL, Lyons J. B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol. 2001;112:1–14
  7. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Ann. Rev. Biochem. 1991;60:443–475
  8. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I, et al.  Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J. Clin. Invest. 1989;83:752–756
  9. Gorski A, Wasik M, Nowaczyk M, Korczak-Kowalska G. Immunomodulating activity of heparin. FASEB J. 1991;5:2287–2291
  10. Buddecke E. Non-anticoagulant function of heparin and heparan sulfate. Hamostaseologie. 1996;16:6–14
  11. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv. Pharmacol. 1999;46:151–208
  12. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M, et al.  Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis. 1994;14:290–302
  13. Castellot JJ, Choay J, Lormeau JC, Petitou M, Sache E, Karnovsky MJ. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells: II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group. J. Cell Biol. 1986;102:1979–1984
  14. Floege J, Eng E, Young BA, Couser WG, Johnson RJ. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int. 1993;43:369–380
  15. Ratner N, Bunge RP, Glaser L. A neuronal cell surface heparan sulfate proteoglycan is required for dorsal root ganglion neuron stimulation of Schwann cell proliferation. J. Cell Biol. 1985;101:744–754
  16. Currie GA. Effect of heparin on mixed lymphocyte cultures. Nature. 1967;215:164–165
  17. Yamamoto H, Fuyama S, Arai S, Sendo F. Inhibition of mouse natural killer cytotoxicity by heparin. Cell. Immunol. 1985;96:409–417
  18. Diccianni MB, Mistry MJ, Hug K, Harmony JA. Inhibition of phospholipase A2 by heparin. Biochim. Biophys. Acta. 1990;1046:242–248
  19. Dua R, Cho W. Inhibition of human secretory class II phospholipase A2 by heparin. Eur. J. Biochem. 1994;221:481–490
  20. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, et al.  Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur. J. Immunol. 1990;20:493–499
  21. Willenborg DO, Parish CR. Inhibition of allergic encephalomyelitis in rats by treatment with sulfated polysaccharides. J. Immunol. 1988;140:3401–3405
  22. Parish CR, Hindmarsh EJ, Bartlett MR, Staykova MA, Cowden WB, Willenborg DO. Treatment of central nervous system inflammation with inhibitors of basement membrane degradation. Immunol. Cell Biol. 1998;76:104–113
  23. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, et al.  Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis. 1992;12:112–127
  24. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, et al.  Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 1999;5:793–802
  25. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 1999;5:803–809
  26. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 2001;108:341–347
  27. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim. Biophys. Acta. 2001;1471:M99–M108
  28. Regan J, Ben-Sasson SA, Sabatino R, Eilat D, Bruno JG, D'Alisa R, et al.  Mimickry of biological macromolecules by polyaromatic anionic compounds. J. Bioact. Compat. Polym. 1993;8:317–337
  29. Brenner T, Poradosu E, Soffer D, Sicsic C, Gazit A, Levitzki A. Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556. Exp. Neurol. 1998;154:489–498
  30. Brenner T, Lisak RP, Rostami A, Pleasure DE, Silberberg DH. Astrocytes, oligodendrocytes, and Schwann cells share a common antigenic determinant that cross-reacts with myelin basic protein: identification with monoclonal antibody. J. Neurosci. 1986;6:1925–1933
  31. Brenner T, Yamin A, Gallily R. Mycoplasma triggering of nitric oxide production by central nervous system glial cells and its inhibition by glucocorticoids. Brain Res. 1994;641:51–56
  32. Davidson FF, Dennis EA, Powell M, Glenney JR. Inhibition of phospholipase A2 by lipocortins and calpactins. An effect of binding to substrate phospholipids. J. Biol. Chem. 1987;262:1698–1705
  33. Matoth I, Pinto F, Sicsic C, Brenner T. Inhibitory effect of carbamazepine on inflammatory mediators produced by stimulated glial cells. Neurosci. Res. 2000;38:209–212
  34. Bashkin P, Razin E, Eldor A, Vlodavsky I. Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix. Blood. 1990;75:2204–2212
  35. Marchetti D, Li J, Shen R. Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. Cancer Res. 2000;60:4767–4770
  36. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J. Clin. Invest. 2002;110:127–136
  37. Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost. 2002;28:53–66
  38. Jones H, Paul W, Page CP. The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin. Br. J. Pharmacol. 2002;135:469–479
  39. Manduteanu I, Voinea M, Capraru M, Dragomir E, Simionescu M. A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology. 2002;65:32–37
  40. Meijer F, Tak C, van Haeringen NJ, Kijlstra A. Interaction between nitric oxide and prostaglandin synthesis in the acute phase of allergic conjunctivitis. Prostaglandins. 1996;52:431–446
  41. Graf H. Endothelial control of cell migration and proliferation. Eur. Heart J. 1993;14(Suppl. I):183–186
  42. Sharma HS, Westman J, Nyberg F, Cervos-Navarro J, Dey PK. Role of serotonin and prostaglandins in brain edema induced by heat stress. An experimental study in the young rat. Acta Neurochir., Suppl. 1994;60:65–70
  43. Heller A, Koch T, Schmeck J, van Ackern K. Lipid mediators in inflammatory disorders. Drugs. 1998;55:487–496
  44. Farooqui AA, Yang HC, Rosenberger TA, Horrocks LA. Phospholipase A2 and its role in brain tissue. J. Neurochem. 1997;69:889–901
  45. Nevalainen TJ, Haapamaki MM, Gronroos JM. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochim. Biophys. Acta. 2000;1488:83–90
  46. Bolton C, Gordon D, Turk JL. A longitudinal study of the prostaglandin content of central nervous system tissues from guinea pigs with acute experimental allergic encephalomyelitis (EAE). Int. J. Immunopharmacol. 1984;6:155–161
  47. Fretland DJ. Potential role of prostaglandins and leukotrienes in multiple sclerosis and experimental allergic encephalomyelitis. Prostaglandins Leukot. Essent. Fat. Acids. 1992;45:249–257
  48. Miao HQ, Ornitz DM, Aingorn E, Ben-Sasson SA, Vlodavsky I. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. J. Clin. Invest. 1997;99:1565–1575

PII: S0022-510X(02)00318-0

Journal of the Neurological Sciences
Volume 206, Issue 1 , Pages 49-57 , 15 January 2003

Article Tools

* Image Usage & Resolution